Ideas to Implementation (I2I) 2026

Winners of the 2026 RISE UP for Breast Cancer Ideas to Implementation (I2I) Award:

JP-Headshot

Jayant Parthasarathy, PhD

Jayant Parthasarathy, PhD is the founder and CEO of Astrin Biosciences, a cancer intelligence company using deep proteomics and AI to detect disease at its earliest stages. Astrin’s first test, Certitude™, is a blood-based test designed to complement existing breast cancer screening by detecting biological signals associated with cancer, independent of breast density. Validated in more than 1,200 women, Certitude has demonstrated the ability to detect breast cancer as early as Stage 0 with high sensitivity and specificity. By helping identify who may need additional imaging or biopsy, this approach could make early detection more accessible, particularly for women with dense breasts and those living in areas with limited access to mammography and advanced imaging. 

Sandra Hammer

Sandra Hammer, PhD

Sandra Hammer, PhD is Associate Director of Scientific Development at Atossa Therapeutics, where she works to advance new approaches to breast cancer prevention and treatment, with a focus on translating emerging science into clinical applications. Her work has centered on (Z)-endoxifen, Atossa’s lead breast cancer therapy and the foundation of the ENDORA program. ENDORA explores a dual-purpose approach combining low-dose (Z)-endoxifen with a progestin-only oral contraceptive for premenopausal women with dense breast tissue, who face both increased breast cancer risk and challenges with early detection. The research will evaluate the safety and tolerability of this combination and whether it can reduce mammary tissue density, generating evidence needed to advance toward clinical trials. By pairing contraception with a potential breast cancer risk-reduction strategy, this work could lay the foundation for a practical new prevention option for women at elevated risk. 

Winners of the 2026 RISE UP for Breast Cancer SPARK Award:

Jennifer Rosenbluth

Jennifer Rosenbluth, MD, PhD

Jennifer Rosenbluth, MD, PhD is a medical oncologist and Associate Professor of Medicine at UCSF whose laboratory develops patient-derived organoid models to study breast cancer biology and prevention. Her research focuses on understanding why women with similar levels of breast cancer risk may have different underlying biology—and therefore may benefit from different prevention strategies. Building on research linking an MRI marker of breast cancer risk, called background parenchymal enhancement (BPE), to distinct tissue biology, her work will use patient-derived organoids to study changes in the immune environment of high-risk breast tissue and determine whether they can be reversed using existing medications. By connecting advanced imaging with the biology of high-risk breast tissue, this research could help identify biological subtypes of breast cancer risk and lay the foundation for more personalized approaches to prevention. 

 

 

Kate Ormiston

Kate Ormiston, PhD, RDN

Kate Ormiston, PhD, RDN is a registered dietitian and breast cancer researcher at The Ohio State University whose work sits at the intersection of nutrition, metabolism, and cancer prevention, with particular expertise in omega-3 fatty acids and preclinical models. Her research focuses on breast cancer risk surrounding pregnancy and breastfeeding, including a period called involution, when the breast returns to its pre-pregnancy state. When breastfeeding does not occur or ends abruptly, this process may create an environment that promotes tumor development and increases breast cancer risk. Her research will test whether prenatal supplementation with the omega-3 fatty acids EPA and DHA can counter these changes in preclinical models. By repurposing a familiar nutritional intervention, this work could lay the foundation for a simple and accessible approach to reducing breast cancer risk during a critical window after pregnancy. 

Jeffrey Weitzel

Jeffrey Weitzel, MD, FACMG

Jeffrey Weitzel, MD, FACMG is Professor and founding Director of the Division of Precision Prevention at the University of Kansas Comprehensive Cancer Center and a pioneer in using genetics and genomics to advance breast cancer risk assessment and prevention. His work focuses on developing more personalized prevention strategies for individuals with inherited cancer risk, including women with BRCA1 or BRCA2 mutations. His BRACERR study explores a hormonal approach designed to suppress ovulation while minimizing exposure to hormones, particularly progesterone, that may contribute to breast cancer risk. Using the existing oral medication elagolix with low-dose hormone add-back and intermittent progesterone, the study will evaluate whether this approach can reduce markers associated with breast cancer risk while remaining tolerable and reversible to preserve fertility. The research could lay the groundwork for a new prevention option for younger women with BRCA mutations, with the potential to extend to other women with inherited breast cancer risk. 

Judges: 

Venture Capital Experts 

Naseem Sayani Headshot

Naseem Sayani, MBA

Naseem is a seasoned VC investor focused on backing and elevating ambitious female founders. Across her VC and angel portfolios, she has made 40+ investments in female-founded teams from Pre-seed to Series A, spanning health tech, fintech, and sustainability. She holds several venture partner roles across the ecosystem at funds including Zero Limits Capital and The Sparrow Fund. Naseem was also a founding partner of Emmeline Ventures, a seed-stage fund based in Los Angeles.

Naseem currently leads the Innovator’s Circle at WHAM (Women’s Health Access Matters), where she focuses on organizing the early-stage startup and fund ecosystem to ensure there are strong companies ready for later-stage investment. She is also a member of the Milken Institute's Women's Health Network.

Alice Zheng

Alice Zheng, MD, MBA, MPH

Alice Zheng has been a women’s health enthusiast throughout her career spanning global health, clinical medicine, and the private sector. She is currently a Partner at Foreground Capital, a venture capital firm investing in early-stage women’s health start-ups. Previously, she was a Principal at Foreground’s precursor funds at RH Capital, where she and the team built one of the largest dedicated venture capital portfolios in women’s health. She serves as a board director for Seven Starling and Millie and as a board observer for AOA and Cofertility.

Celina Johnson headshot

Celina Johnson, MBA

Celina Johnson is a seasoned investor and startup executive with over 20 years of experience She is currently the Co-founder and Managing Partner of the Goddess Fun+d, dedicated to reclaiming investing as a joyful and intentional act while supporting women entrepreneurs who are creating positive global impact.

Ms. Johnson began her career in investing at KKR. This foundational experience in global private equity paved the way for her 15+ years as a startup executive, where she gained deep operational knowledge in scaling companies. She combines this background in rigorous investment analysis and operational excellence with a passion for soulful connection and doing business in a radically new way.

Industry Experts

Beth Garner

Beth Garner, MD, MPH

Elizabeth (Beth) Garner was Chief Scientific Officer of Ferring Pharmaceuticals US, a mid-size global company focused on reproductive and maternal health, microbiome and gastrointestinal therapeutics, and uro-oncology. She is also the Immediate Past President of the American Medical Women’s Association (AMWA).

 

Scott St. Germain JPG

Scott St. Germain, MBA

Scott St. Germain serves as Vice President and U.S. General Manager at Genentech, a leading biotechnology company, located in South San Francisco. In this capacity, he oversees all business teams, activities, and investments to ensure that patient care is optimized in specific therapeutic areas.  Scott also is responsible for guiding the commercialization of innovative pipeline molecules for both the U.S. and global markets. Scott has held numerous leadership roles in both the biotech and governmental sectors.  At Genentech, he has led multiple different types of teams across the organization's expansive product and service portfolio.  Most recently, he played a key role in launching the first biologic to treat severe food allergies in children and adults.  Scott’s expertise in life sciences spans across multiple disciplines ranging from commercial strategy, access and managed care, patient services, pricing, public policy, account management, and sales and marketing.

Science and Regulatory Experts

Diana Blithe

Diana Blithe, PhD

Diana Blithe, PhD is the Program Chief of the Contraceptive Development Program (CDP) at the National Institute of Child Health and Human Development (NICHD).

 

 

 

Larry Norton

Larry Norton, MD

Larry Norton, MD is a medical oncologist and Norna S. Sarofim Chair of Clinical Oncology at Memorial Sloan Kettering. He is also the Founding Medical Director of the Evelyn H. Lauder Breast Cancer. In addition he is the Founding Scientific Director at the Breast Cancer Research Fund (BCRF).

Abigail Liberty Headshot.JPG

Abigail Liberty, MD

Dr. Abigail Liberty, MD, MSPH, is an obstetrician–gynecologist at OHSU in Portland, Oregon, with subspecialty expertise in Complex Family Planning. She provides full-spectrum reproductive care, including specialized gynecologic care for cancer survivors. Her research as a Women’s Reproductive Health Research Scholar focuses on the differential effects of progestins and anti-progestins on breast health.

Patient Advocates

Heather Salazar.jpeg

Heather Salazar

Heather Salazar is a cancer survivor, patient advocate, and the President and Chief Executive Officer of Pink Ribbon Good, a nonprofit dedicated to providing free, direct support services to individuals and families affected by breast and gynecological cancers. Drawing from lived experience, she is a leading voice in patient-centered advocacy, working to ensure that no one faces cancer alone.

 

Susie Brain RISE UP headshot.jpg

Susie Brian

Susie Brain is a breast cancer survivor of over 20 years and an experienced patient, research, and legislative advocate, working to support the advancement of medical research that will prevent and treat cancer.  She plays a significant role in integrating the patient perspective into scientific research and healthcare policy. Based in the San Francisco Bay Area, her work has had a national impact through collaborations with various cancer organizations and institutions. She is a member of UCSF’s Breast Science Advocacy Core and supports the nationwide I-SPY 2 and WISDOM clinical trials.   


I2I Agenda – Thursday, February 19th, 2026

9:00-11:00I2I Pitch Competition at the Feinstein’s Hotel Nikko - (Reservation Required) 
11:00-11:40Re-Imagine Toxicity and Reducing Drug Manufacturing costs: A call to action to VCs
11:40-11:50I2I Closing Remarks (Results Announced Saturday)

The Ideas to Implementation competition will take place on the first day of RISE UP, on February 19th, 2026. The day begins with the I2I Pitch Competition at Feinstein’s Hotel Nikko, where innovators showcase their ventures to a panel of judges and investors. Following this, a featured session, Re-Imagine Toxicity and Reducing Drug Manufacturing Costs: A Call to Action to VCs, challenges stakeholders to rethink industry practices and funding priorities. The competition concludes with closing remarks from I2I, with competition results to be announced on Saturday.

What is the Ideas to Implementation Competition? 

Significant strides have been made in understanding that the biology of breast cancer is not homogenous, leading to dramatic advances in treatment. Yet despite this progress, the incidence of breast cancer continues to rise. We need to dramatically reshape how we approach the prevention of breast cancer. There is a profound opportunity to affect this trend–one that requires an out-of-the-box approach and a paradigm shift in prevention.

 

Breast cancer risk starts early, with factors such as the timing of menarche influenced by exercise and diet, and it continues across a woman’s lifetime through hormonal exposures including birth control, fertility treatments, postpartum weaning, and menopause management. For example, nearly 65% of women ages 15–49 use some form of contraception, yet most were formulated before we fully understood breast cancer risk. Pharmaceutical products are often designed for a single purpose, but we have not leveraged their potential to serve multiple goals; for example, contraceptives that can also reduce breast cancer risk or medications that can treat fibroids and reduce breast cancer.

 

The RISE UP (Revolutionizing Investigations to StEp Up Prevention) interdisciplinary meeting is designed to spark this paradigm shift: to rethink, reformulate, and reimagine the products widely used in women’s health such that they also integrate cancer prevention. 

 

The RISE UP “Ideas to Implementation” session bridges academia and venture capital, inviting all sectors–researchers, providers, policymakers, and industry–to develop bold, practical strategies that embed prevention into the standard of care.

 

This competition is explicitly designed to harness innovation and frontier-breaking solutions that reduce disparities, optimize women’s health, and dramatically decrease the incidence, morbidity, and mortality from breast cancer.

What are we looking for?

  • Prevention across the lifecourse: Ideas that leverage what we know about breast cancer biology, treatment, and hormonal management as a baseline to expand and reimagine how we approach breast cancer prevention across a woman’s lifecourse
  • Biomarker-driven prevention tools: Risk assessment tools that utilize blood, tissue or imaging biomarkers or products to better understand risk and response are of particular interest as well. 
  • Dual-impact therapeutics: Exploration of medications or biologic pathways that not only mitigate specific conditions but also lower breast cancer risk or delay disease progression.

Where does my idea best fit in this competition?

There are two branches of this competition. The SPARK award and the Implementation award. 
The “SPARK” award aims to foster early-stage research ideas and collaborations. Interested parties should submit a proposal that outlines their idea, addresses how it is innovative and considers a holistic approach to breast cancer prevention. The most promising proposals will be selected to prepare a more detailed pitch deck, and finalists will be invited to present their ideas live in front of an outstanding panel of judges at the RISE UP for Breast Cancer meeting to be held in San Francisco, CA from February 19-21st, 2026. 

SPARK awards will focus on transformative early-stage research efforts and/or collaborations to create a new program and approach. Selected awardees will receive an award of up to $50k.

The Implementation Award supports seed-stage innovations by lowering barriers to commercialization and encouraging venture and industry investment in prevention. Finalists will present poster proposals and a subset will be invited to an in-person “Shark Tank”-style pitch session at the RISE UP for Breast Cancer Conference on February 19, 2026. Pitches will be judged by investors, FDA leaders, scientists, advocates, and community leaders on feasibility and potential impact. Winners will have the opportunity to work with clinical partners within the RISE UP ecosystem identified at the conference to test their ideas in the clinic.

Follow this flowchart to assess which branch of the competition best suits your idea!

I2I Flowchart

Examples from 2024 winners & concepts we would be particularly interested in having further submissions in

  • Contraceptives have been associated with decreases in ovarian and colon cancer, but not yet with decreases in breast cancer. What if we could redesign contraceptives to reduce breast cancer risk as well? 
  • Testing a small implant that combines testosterone with an aromatase inhibitor to rebalance hormones in breast tissue. This study, using advanced imaging/omics, hopes to lower the risk of ER+ and ER- breast cancers by changing the local environment in the breast to provide a safe, effective prevention option. 
  • An app, FitnessCan, that gives personalized exercise programs for cancer patients to help them safely regain strength, reduce fatigue, and improve recovery after treatment. 
  • Utilizing new FDA-approved weight loss drugs (incretin mimetics) to reduce breast cancer risk. By identifying biomarkers that predict which patients will benefit , this project aims to personalize medication recommendations and reduce the risk of developing cancer for women with obesity. 
  • Exploring the use of mifepristone (a progesterone blocker) for breast cancer prevention and developing epigenetic tests that track early cancer risk changes in breast tissue or even in self-collected samples. The combination of preventive drugs and real-time risk monitoring could personalize prevention strategies for high-risk women.
  • Black women are diagnosed with fibroids roughly three times as frequently as white women. Anti-progestins, such as ulipristal acetate (UPA), have been shown to reduce symptomatic fibroids. As anti-progestins have been independently associated with the reduction of breast cancer risk, this presents an exciting, underexplored opportunity: could a single class of agents be harnessed to address both fibroids and breast cancer risk?
  • Exploring new biomarkers that predict breast cancer risk and response that could better accelerate breast cancer prevention trials. 
  • New risk assessment tools that could better predict who is at risk for different types of breast cancer.